

HIV DART 2008
Scientific Program

TUESDAY, DECEMBER 9, 2008

18:00 Welcome Reception

WEDNESDAY, DECEMBER 10, 2008

<p>8:00 Opening Remarks and Presentation of Gertrude Elion Distinguished Lecturer Award Raymond F. Schinazi <i>Emory University/Veterans Affairs Medical Center, USA</i> Robert Murphy <i>Northwestern University, USA</i></p> <p>8:15 Gertrude Elion Distinguished Lecturer Award Approaches towards HIV-1 Eradication: Harnessing Cellular Restrictions Mario Stevenson <i>University of Massachusetts Medical School, USA</i></p> <p>Pathogenesis and Targeted Design <i>Chairs:</i> Daria Hazuda <i>Merck Research Labs, USA</i> Leonid Margolis <i>National Institute of Child Health and Human Development, USA</i></p> <p>8:55 Understanding HIV Maturation using Electron Cryotomography Elizabeth Wright <i>California Institute of Technology, USA</i></p> <p>9:15 Vpu and its Cellular Targets Paul Spearman <i>Emory University School of Medicine, USA</i></p> <p>9:35 Cell Penetrating Peptides: From Molecular Mechanisms to Therapeutics Gilles Divita <i>CNRS, France</i></p> <p>9:55 Panel Discussion</p> <p>10:15 Break</p> <p>Toward HIV Eradication I <i>Chairs:</i> Bruce Polsky <i>St. Luke's Roosevelt Hospital Center, USA</i> Matthias Götte <i>McGill University, Canada</i></p> <p>10:35 Complementary Mechanisms of Nucleoside Analog Resistance from Structural Studies of HIV-1 Reverse Transcriptase Eddy Arnold <i>Rutgers University, USA</i></p> <p>10:55 Dose Response Curve Slope Sets Class Specific Limits on Inhibitory Potential of Anti-HIV Drugs Robert Siliciano <i>Johns Hopkins University School of Medicine and Howard Hughes Medical Institute, USA</i></p> <p>11:15 Pharmacology, Metabolism and Transport of HIV Drugs into Viral Reservoirs Saye Khoo <i>University of Liverpool, UK</i></p> <p>11:35 Panel Discussion</p>	<p>Oral Abstract Session I <i>Chairs:</i> Charles Boucher <i>Erasmus Medical Center Rotterdam and University Medical Centre Utrecht, the Netherlands</i> Adrian Ray <i>Gilead Sciences, Inc., USA</i></p> <p>11:55 Immunotoxins to Selectively Deplete Reservoirs of HIV-infected Cells that Persist in the Face of Highly Suppressive Antiretroviral Therapy Edward Berger <i>National Institutes of Health, USA</i></p> <p>12:05 Development of Pyrimidinedione NNRTIs with a High Genetic Barrier to Resistance Robert Buckheit <i>ImQuest BioSciences, USA</i></p> <p>12:15 Development of VS411, a Virostatic Drug Fixed Dose Combination (FDC) Designed to Inhibit both HIV and Immune Hyperactivation Franco Lori <i>ViroStatics Srl, Italy</i></p> <p>12:25 Inhibiting Vpu Function with the Novel Compound BIT225, Results in Inhibition of HIV-1 Release from Human Macrophage Reservoirs John Wilkinson <i>Biotron Limited, Australia</i></p> <p>12:35 Lunch</p> <p>14:00 Free Afternoon</p> <p>16:00 – 18:30 Poster Session</p> <p>Toward HIV Eradication II <i>Chairs:</i> Raymond F. Schinazi <i>Emory University/Veterans Affairs Medical Center, USA</i> Ian Sanne <i>Wits Health Consortium, South Africa</i></p> <p>18:30 State of the Art Lecture Integrase Inhibitors: New Insights into Mechanism of Action and Pharmacology with Implications for Treatment and Prevention Strategies Daria Hazuda <i>Merck Research Labs, USA</i></p> <p>19:00 A Non-human Primate Model for Development of AIDS Eradication Strategies Thomas North <i>University of California, Davis, USA</i></p> <p>19:20 Diminution of HIV Latency through Blockage of Arginine Methylation of Viral Proteins Mark Wainberg <i>McGill University AIDS Centre, Canada</i></p> <p>19:40 Panel Discussion</p>
--	---

HIV DART 2008 Scientific Program

THURSDAY, DECEMBER 11, 2008

Prevention and Drug Resistance <i>Chairs:</i> Mark Wainberg <i>McGill University AIDS Centre, Canada</i> Douglas Mayers <i>Idenix Pharmaceuticals, Inc., USA</i>		Oral Abstract Session II <i>Chairs:</i> Charles van der Horst <i>University of North Carolina at Chapel Hill, USA</i> Paul Spearman <i>Emory University, USA</i>	
8:00	Presentation of David Barry DART Achievement Award Robert Murphy <i>Northwestern University, USA</i> <i>The Award will be given to Dr. Larder by Mrs. Gracia Barry</i>	11:30	Glycan Deletions in the HIV-1 gp120 V1/V2 Domain Compromise Viral Infectivity, Sensitize the Mutant Virus Strains to Carbohydrate Binding Agents and Represent a Specific Target for Therapeutic Intervention Joeri Auwerx <i>K.U. Leuven, Rega Institute for Medical Research, Belgium</i>
8:10	David Barry DART Achievement Award Milestones in HIV Drug Resistance: From <i>in Vitro</i> to <i>in Silico</i> Brendan Larder <i>HIV Resistance Response Database Initiative (RDI), UK</i>	11:40	Gag NC/p1 Protease Resistance Mutations can cause Selection of Additional NC/p1 Changes to Optimize Cleavage Efficiency and Replicative Capacity Monique Nijhuis <i>University Medical Centre Utrecht, Netherlands</i>
8:50	STOP HIV/AIDS: Seek and Treat for Optimal Prevention of HIV/AIDS Julio Montaner <i>British Columbia Centre for Excellence in HIV/AIDS, Canada</i>	11:50	Safety, Tolerability and Efficacy of Darunavir/ritonavir in Treatment-experienced Women with HIV Infection: Interim Analysis of GRACE (Gender, Race, and Clinical Experience) Carmen Zorrilla <i>University of Puerto Rico School of Medicine, USA</i>
9:10	Transmission of Drug Resistant HIV: Patterns of Resistance to New Antiretroviral Agents and their Clinical Relevance Charles Boucher <i>Erasmus Medical Center Rotterdam and University Medical Centre Utrecht, the Netherlands</i>	12:00	96-Week (wk) Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced Patients Christine Katlama <i>Hôpital Pitié-Salpêtrière, France</i>
9:30	Panel Discussion	12:10	Lunch on your own
9:50	Break	13:30	Free Afternoon
HIV Therapy in Developing Countries <i>Chairs:</i> Christine Katlama <i>Hôpital Pitié-Salpêtrière, France</i> Douglas Dieterich <i>Mount Sinai School of Medicine, USA</i>		HIV/Hepatitis and Other Co-infections <i>Chairs:</i> Tracy Swan <i>Treatment Action Group, USA</i> Joep Lange <i>University of Amsterdam, the Netherlands</i>	
10:10	Experiences in HIV Treatment in Developing Countries Ian Sanne <i>Wits Health Consortium, South Africa</i>	17:00	State of the Art Lecture The Aging Liver in the HIV Population Douglas Dieterich <i>Mount Sinai School of Medicine, USA</i>
10:30	To Wean or not to Wean: Prevention of Mother-to-child Transmission through Breast Milk Charles van der Horst <i>University of North Carolina at Chapel Hill, USA</i>	17:30	Co-infection with HCV and HBV: When and How to Treat? Bruce Polsky <i>St. Luke's Roosevelt Hospital Center, USA</i>
10:50	Topical Microbicides: Moving towards Topical Pre-exposure Prophylaxis (PrEP) Sharon Hillier <i>University of Pittsburgh School of Medicine, USA</i>	Poster Discussion 17:50 Poster Review, Part I Joep Lange <i>University of Amsterdam, the Netherlands</i>	
11:10	Panel Discussion	18:20	Poster Review, Part II Adrian Ray <i>Gilead Sciences, Inc., USA</i>
		20:00	Gala Party

HIV DART 2008 Scientific Program

FRIDAY, DECEMBER 12, 2008

Novel Therapeutic Approaches: Antiviral Mechanism and Predictive Toxicology Chairs: Carmen Zorrilla <i>University of Puerto Rico School of Medicine, USA</i> Richard Pollard <i>University of California, Davis Medical Center, USA</i>		Oral Abstract Session III Chairs: Lisa Dunkle <i>Schering-Plough Research Institute, USA</i> José Rodríguez-Orengo <i>Instituto de Ciencias Forenses, Puerto Rico, USA</i>	
8:00	State of the Art Lecture Optimizing HAART Therapy in the Era of Integrase and Entry Inhibitors Christine Katlama <i>Hôpital Pitié-Salpêtrière, France</i>	11:50	Comparison of Two Human Pancreatic Cell Lines for Predicting Mitochondrial Toxicity by Nucleoside Analogs Leda Bassit <i>Emory University School of Medicine and VA Medical Center, USA</i>
8:30	IDX-899 -- A Novel Once-a-day Second Generation NNRTI for the Treatment of HIV/AIDS Douglas Mayers <i>Idenix Pharmaceuticals, Inc., USA</i>	12:00	ARTEMIS: Efficacy and Safety of Darunavir/ritonavir (DRV/r) 800/100 mg Once-daily vs. Lopinavir/ritonavir (LPV/r) in Treatment-naïve, HIV-1-infected Patients at 96 Weeks Dushyantha Jayaweera <i>University of Miami, USA</i>
8:50	Vicriviroc: A Next Generation CCR5 Antagonist for Treatment of HIV Lisa Dunkle <i>Schering-Plough Research Institute, USA</i>	12:10	Etravirine (ETR; TMC125) Demonstrates Favorable Efficacy and Safety in the Phase III DUET Trials Regardless of Geographic Location Christine Katlama <i>Hôpital Pitié-Salpêtrière, France</i>
9:10	Amdoxovir Combined with Low Dose AZT for HIV-1 Therapy Robert Murphy <i>Northwestern University, USA</i>	12:20	Pharmacokinetics and Short-term Safety and Efficacy of Once-daily Etravirine Without and With Once-daily Darunavir/ritonavir in Antiretroviral-naïve HIV-1 Infected Adults James Witek <i>Tibotec Therapeutics, USA</i>
9:30	Break		
9:50	A New Era in HIV-antiretroviral Therapy: Darunavir, Etravirine and TMC278 Eric Lefebvre <i>Tibotec, the Netherlands</i>	Late Breaker Presentations	
10:10	Low Potential for Class Related Toxicity of Next Generation Nucleotide Analog GS-9148 Adrian Ray <i>Gilead Sciences, Inc., USA</i>	12:30	Genome-scale RNAi Screen for Host Factors Required for HIV Replication Amy Espeseth <i>Merck & Co., Inc., USA</i>
10:30	Mechanisms Associated with Delayed HIV RT Chain-termination Matthias Götte <i>McGill University, Canada</i>	12:40	Quantification of HIV Tropism by "Deep" Sequencing Shows a Broad Distribution of Prevalence of X4 Variants in Clinical Samples Associated with Virological Outcome Richard Harrigan <i>BC Centre for Excellence in HIV/AIDS and University of British Columbia, Canada</i>
10:50	Panel Discussion		
11:10	Break		
11:30	Special Lecture Acyclovir as an HIV-1 RT Inhibitor in Herpesvirus-infected Human Tissues Leonid Margolis <i>National Institute of Child Health and Human Development, USA</i>	12:50	Antiviral Activity and Tolerability of PRO 140, a Humanized Monoclonal Antibody to CCR5 Stephen Morris <i>Progenics Pharmaceuticals, Inc., USA</i>
		13:00	Closing Remarks Raymond F. Schinazi <i>Emory University/Veterans Affairs Medical Center, USA</i>
		13:10	Lunch